Intec Pharma Reports Results for the Third Quarter of 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Intec Pharma Reports Results for the Third Quarter of 2015

JERUSALEM, ISRAEL--(Marketwired - Nov 5, 2015) -   Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP) ("Intec Pharma" or the "Company"), an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its financial results for the third quarter ended September 30, 2015 and provided a business update. Results are presented in New Israel Shekels (NIS) with a convenience translation to US$ provided using the Bank of Israel exchange rate of NIS 3.923 to $1.00 at September 30, 2015.

Financial highlights for the three months ended September 30, 2015:

  • Research and Development Expenses, net for the three months ended September 30, 2015 amounted to approximately NIS 3.6 million ($908,000), compared to approximately NIS 3.1 million for the three months ended September 30, 2014. The increase was primarily due to preparation activities related to the Company's planned phase III clinical trial of the Company's Accordion Pill Carbidopa/Levodopa, or AP-CDLD, which is being developed for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, of approximately NIS 1.3 million and an increase of approximately NIS 420,000 in payroll and related expenses and share based compensation, net of increase in Office of Chief Scientist, or OCS, grants of approximately NIS 600,000 and net of an increase of NIS 563,000 received from Biogen MA Inc. pursuant to the Company's previously announced development agreement with Biogen.
  • General and Administrative Expenses for the three months ended September 30, 2015 amounted to approximately NIS 3.0 million ($762,000) compared to approximately NIS 1.9 million for the three months ended September 30, 2014. The increase was primarily due to increases of approximately NIS 533,000 in professional services and approximately NIS 363,000 in payroll and related expenses and share based compensation.
  • Financial Income, net for the three months ended September 30, 2015 consisted of foreign currency exchange income in the amount of approximately NIS 3.4 million and financial income from interest on cash equivalents in the amount of approximately NIS 29,000. In addition to bank fees, the Company also had financial expenses from change in fair value of derivative financial instruments in the amount of approximately NIS 2.3 million.
  • Loss and Comprehensive Loss - for the three months ended September 30, 2015, we reported a loss and comprehensive loss of NIS 5.4 million ($1.4 million) or NIS 0.62 ($0.16) per share, basic and diluted, compared with a loss and comprehensive loss of NIS 5.0 million or NIS 1.09 per share, basic and diluted, for the three months ended September 30, 2014.

Financial highlights for the nine months ended September 30, 2015:

  • Research and Development Expenses, net for the nine months ended September 30, 2015 amounted to approximately NIS 10.8 million ($2.8 million) compared to approximately NIS 8.9 million for the nine months ended September 30, 2014. The increase was primarily due to preparation activities related to the Company's planned phase III clinical trial of AP-CDLD of approximately NIS 1.7 million and an increase of approximately NIS 841,000 in payroll and related expenses and share based compensation, net of increase in OCS grants of approximately NIS 1 million in the nine months ended September 30, 2015.
  • General and Administrative Expenses for the nine months ended September 30, 2015 amounted to approximately NIS 7.5 million ($1.9 million) compared to approximately NIS 6.9 million for the nine months ended September 30, 2014. The increase was primarily due to an increase of approximately NIS 418,000 in payroll and related expenses and share based compensation.
  • Other Gains, net for the nine months ended September 30, 2015 consisted of change in the fair value of the financial assets at fair value through profit or loss of approximately NIS 29,000 ($7,400), compared to approximately NIS 1.0 million for the nine months ended September 30, 2014, consisted primarily of indemnification from an insurance company of approximately NIS 887,000.
  • Financial Income, net for the nine months ended September 30, 2015 consisted of foreign currency exchange income in the amount of approximately NIS 3.2 million and financial income from interest on cash equivalents in the amount of approximately NIS 75,000. In addition to bank fees, the Company also had financial expenses from change in fair value of derivative financial instruments in the amount of approximately NIS 1.4 million.
  • Loss and Comprehensive Loss - for the nine months ended September 30, 2015 we reported a loss and comprehensive loss of NIS 16.3 million ($ 4.2 million) or NIS 2.49 ($ 0.63) per share, basic and diluted, compared with a loss and comprehensive loss of NIS 11.5 million or NIS 2.49 per share, basic and diluted, for the nine months ended September 30, 2014.
  • Net Cash Used in Operating Activities for the nine months ended September 30, 2015 was approximately NIS 14.2 million ($3.6 million) compared to approximately NIS 11.9 million in the nine months ended September 30, 2014. This increase primarily resulted from an increase in our loss and comprehensive loss of approximately NIS 4.9 million, net of an increase in income and expenses not involving cash flows of approximately NIS 2.4 million.
  • Net Cash Used in Investment Activities for the nine months ended September 30, 2015 was approximately NIS 3.7 million ($ 945,000), compared to approximately NIS 9.3 million of net cash provided by investment activities for the nine months ended September 30, 2014. The change primarily resulted from an increase in acquisition of financial assets at fair value through profit or loss of approximately NIS 10.1 million netted by an increase in purchase of property and equipment of approximately NIS 3.1 million.
  • Net Cash Provided by Financing Activities for the nine months ended September 30, 2015 was approximately NIS 125.5 million ($32.0 million) compared to approximately NIS 0.6 million for the nine months ended September 30, 2014. The positive cash flow from financing activities for the nine months ended September 30, 2015 was due to proceeds from the issuance of shares through an initial public offering in the U.S., net of issuance costs, in the amount of approximately NIS 118.2 million and from the exercise of Series 7 warrants in an amount of approximately NIS 7.3 million.
  • Cash, cash equivalents and Financial assets at fair value as of September 30, 2015 were approximately NIS 140.7 ($35.9 million), compared to NIS 30.1 million as of December 31, 2014.

Zeev Weiss, CEO of Intec Pharma, commented: "We are excited with our U.S. listing, which we believe will bring new interest to our Accordion Pill platform technology, including our focus on AP-CDLD, our lead product candidate, for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients."

Recent highlights

  • On October 22, 2015, the Company announced that it has been informed by the European Patent Office (EPO) that a European patent will be granted November 4, 2015 on the Company's European Patent Application for a "Method and Apparatus for Forming Delivery Devices for Oral Intake of an Agent". The patent, number EP 1981465, protects a method of producing Intec's Accordion Pill platform, and the Accordion Pill produced thereby. The platform may be made from any suitable substances, and is intended for oral delivery of any pharmaceutically active agent of interest. The patent is currently scheduled to remain in force until January 18, 2027.
  • On October 12, 2015, the company announced on topline results of a Food Effect, pharmacokinetic, or PK, study of AP-CDLD 50/500mg for the treatment of Parkinson's disease symptoms. The results demonstrated that plasma concentrations of carbidopa and levodopa were similar, with no statistically significant differences in all PK parameters measured, when AP-CDLD was taken with various food compositions. This suggests that the treatment with AP-CDLD, intended to be taken b.i.d (two times a day) or t.i.d (three times a day) with food, is independent of the food content.
  • On August 9, 2015, the Company closed its underwritten public offering in the U.S. of 5,025,000 ordinary shares at a price to the public of $6 per Share. The Company received proceeds from the public offering of approximately $26.5 million, net of commissions to the underwriters and offering expenses. On September 17, 2015, the underwriters partially exercised their overallotment option and purchased an additional 638,750 ordinary shares at a price to the public of $6 per share. The Company received proceeds of approximately $3.48 million related to the overallotment exercise, net of commissions to the underwriters and offering expenses, bringing the total net proceeds to the Company from the initial public offering to approximately $30 million. Maxim Group LLC and Roth Capital Partners acted as joint book-running managers for the offering.
   
   
INTEC PHARMA LTD.  
CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION  
   
                Convenience translation into USD  
    December 31,     September 30,     September 30,  
    2014     2015     2015  
    (Audited)     (Unaudited)        
    NIS in thousands     In thousands  
Assets                  
CURRENT ASSETS:                  
  Cash and cash equivalents   22,287     132,394     33,748  
  Financial assets at fair value through profit or loss   7,820     8,270     2,108  
  Restricted bank deposits   292     242     62  
  Other receivables   1,120     1,900     484  
    31,519     142,806     36,402  
NON-CURRENT ASSETS -                  
  Property and equipment   17,101     17,128     4,366  
TOTAL ASSETS   48,620     159,934     40,768  
                   
Liabilities and equity                  
CURRENT LIABILITIES -                  
  Accounts payable and accruals:                  
    Trade   716     1,044     266  
    Other   6,503     7,002     1,785  
    7,219     8,046     2,051  
NON-CURRENT LIABILITIES -                  
  Derivative financial instruments   4,528     1,826     465  
COMMITMENTS AND CONTINGENT LIABILITIES                  
TOTAL LIABILITIES   11,747     9,872     2,516  
                   
EQUITY:                  
  Ordinary shares   2,701     2,701     689  
  Share premium   198,566     328,985     83,860  
  Warrants   2,249     -     -  
  Accumulated deficit   (166,643 )   (181,624 )   (46,297 )
TOTAL EQUITY   36,873     150,062     38,252  
TOTAL LIABILITIES AND EQUITY   48,620     159,934     40,768  
                   
                   
                   
INTEC PHARMA LTD.  
CONDENSED INTERIM STATEMENT OF COMPREHENSIVE LOSS  
   
        Convenience translation into USD  
  Three months ended September 30     Nine months ended September 30     Three months ended September 30,     Nine months ended September 30,  
  2014     2015     2014     2015     2015     2015  
  (Unaudited)        
  NIS in thousands     In thousands  
RESEARCH AND DEVELOPMENT EXPENSES (4,114 )   (5,738 )   (13,242 )   (16,275 )   (1,463 )   (4,148 )
LESS - PARTICIPATION IN RESEARCH AND DEVELOPMENT EXPENSES 1,014     2,176     4,300     5,517     555     1,406  
RESEARCH AND DEVELOPMENT EXPENSES, net (3,100 )   (3,562 )   (8,942 )   (10,758 )   (908 )   (2,742 )
GENERAL AND ADMINISTRATIVE EXPENSES (1,927 )   (2,989 )   (6,945 )   (7,453 )   (762 )   (1,900 )
OTHER GAINS (LOSSES), net (2 )   42     1,035     29     11     7  
OPERATING LOSS (5,029 )   (6,509 )   (14,852 )   (18,182 )   (1,659 )   (4,635 )
FINANCIAL INCOME 306     3,460     3,483     3,290     882     839  
FINANCIAL EXPENSES (300 )   (2,331 )   (75 )   (1,424 )   (594 )   (363 )
FINANCIAL INCOME, net 6     1,129     3,408     1,866     288     476  
LOSS AND COMPREHENSIVE LOSS (5,023 )   (5,380 )   (11,444 )   (16,316 )   (1,371 )   (4,159 )
  NIS     U.S.D  
BASIC AND DILUTED LOSS PER ORDINARY SHARE (1.09 )   (0.62 )   (2.49 )   (2.49 )   (0.16 )   (0.63 )
                                   

About Intec Pharma Ltd. Intec Pharma is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline currently includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CDLD, is being developed for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and Accordion Pill Zaleplon, or AP-ZP, is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance..

Forward Looking Statements This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements involve certain risks and uncertainties, including, among others, risks impacting the ability of the Company to complete any public offering of its securities because of general market conditions or other factors and risks that could cause the Company's results to differ materially from those expected by Company management. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, and include the following: the company's ability to develop and commercialize its product candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company's clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company's hormone therapy drug candidates; the availability of reimbursement from government authorities and health insurance companies for the company's products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.

Contact Zeev Weiss Chief Executive Officer (+972) (2) 586-4657 Zeev@intecpharma.com PCG Advisory Investors: Vivian Cervantes Managing Director Phone (+1) 212 554-5482 Media Sean Leous Managing Director Phone (+1) 646 863-8998

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 111

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 142

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 0

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 92

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 156

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 137

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

Mission Rock Takes Charge of Seasons at Horsetooth

Updated Category News Views 20

Mission Rock Shakes Up Colorado's Apartment Market Here's one for the books: Mission Rock Residential, known for its no-nonsense approach to property management, just snagged a juicy piece of the market by taking over management at Seasons at Horsetooth Crossing in Fort Collins. Fort Collins isn't just some random name on the map—it's a hotbed for real estate, thanks to...

Continue Reading
Teck Resources Confirms Quarterly Dividend for Shareholders

Updated Category News Views 175

Teck Resources Declares New Dividend for Shareholders Teck Resources Limited (NYSE: TECK) has made an exciting announcement that will please its investors. The company has declared a quarterly dividend of $0.125 per share designated for its outstanding Class A common shares and Class B subordinate voting shares. This dividend is set to be paid on March 31 to all...

Continue Reading
Empowering Voices: The Impact of the AWDPI Conference

Updated Category News Views 300

Empowering Women Through Innovative Discussions The recent conference organized by the Asian Women Development Plan International brought together over 10,000 individuals passionate about empowering Asian women. This pivotal gathering, titled "The Conference of Asian Women Development International 2024", served as a beacon for women's issues, fostering a collaborative...

Continue Reading
O2Gold Shares Significant Updates on Quebec Aur Acquisition

Updated Category News Views 205

O2Gold's Exciting Update on Quebec Aur Acquisition O2Gold Inc. (NEX:OTGO.H), a dynamic player in the mineral exploration landscape, is thrilled to provide an update on its ongoing journey towards acquiring a gold mining exploration property in Quebec. This acquisition is through the purchase of Quebec Aur Ltd., with the transaction details specified in a share exchange...

Continue Reading
Skycorp Solar Group Limited Announces Major IPO Initiative

Updated Category News Views 187

Skycorp Solar Group Limited Announces Major IPO Initiative Skycorp Solar Group Limited (PN) has made a notable move by filing for an initial public offering (IPO) that encompasses 2,000,000 shares. The pricing is positioned attractively between $4 and $5 per share, appealing to a diverse range of potential investors. Understanding the IPO Process An IPO is a crucial step...

Continue Reading